Aethlon Medical Inc. Unveils Presentation on Hemopurifier® Blood Purification Device and Its Potential in Oncology and Infectious Disease Treatment
Reuters
Sep 04
<a href="https://laohu8.com/S/AEMD">Aethlon Medical Inc</a>. Unveils Presentation on Hemopurifier® Blood Purification Device and Its Potential in Oncology and Infectious Disease Treatment
Aethlon Medical Inc. has presented an overview of its Hemopurifier® technology, highlighting its unique mechanism of action in blood purification. The device has demonstrated potential in early clinical trials to clear enveloped viruses and extracellular vesicles (EVs) both in vitro and in patients. Aethlon has received two FDA "Breakthrough Device" designations for its applications in advanced/metastatic cancer and the treatment of life-threatening viruses without approved therapies. The company is actively enrolling patients in an oncology trial in Australia and is engaged in ongoing research and development for Long COVID. The Hemopurifier® has been administered in 164 sessions across 38 patients, showing a favorable safety profile. Aethlon's broad patent portfolio supports its competitive advantage, with opportunities for future expansion in various therapeutic areas. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on September 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.